Surgery is more effective than drug in hyperparathyroidism post-kidney transplantation

December 16, 2015

A study led by researchers from the Nephrology group at Bellvitge Biomedical Research Institute (IDIBELL) and the University Hospital of Bellvitge (HUB), compared the results of surgery with drug therapy in patients with tertiary hyperparathyroidism, ie after a kidney transplant. The results of the research have been published in the journal of greatest impact in the Journal of the American Society of Nephrology.

This is the first clinical trial comparing these two treatments for this disease and has been funded by the Carlos III Health Institute within the call for independent clinical research projects.

Tertiary hyperparathyroidism

50% of patients with a kidney transplant presents tertiary hyperparathyroidism. This complication involves too much calcium, causing cardiovascular worsening by hypercalcemia, bone loss, and worsens the survival of the transplanted organ.

The study was performed in 30 patients. Half of them are operated and the other half have been treated with the usual drug. Researchers have found that surgery totally controls hypercalcemia, normalizes the secretion of parathyroid hormone (PTH) and improves bone density. While treatment only controls excess calcium in 67% of cases, has no effect on PTH and even slows the decline in bone density and does not stop the process.

The principal researcher of the study, Josep Maria Cruzado, explained that "if we have a surgical team with experience in this type of operation, our recommendation in these cases is to operate because it is positive both from the viewpoint of efficiency, since surgery It is a curative treatment, and from the economic point of view: the cost of surgery is equivalent to 14 months of treatment, and the drug must be taken chronically and can not be stopped."

The results of this study could change the clinical practice of tertiary hyperparathyroidism.

Cruzado has also explained that it is a minimally invasive surgery and involves only one day of hospitalization.
-end-
This study was coordinated by Josep M Cruzado, HUB Nephrology and Pablo Moreno of Surgery HUB and also collaborated in this work the nephrology, surgery, rheumatology and radiology services at HUB and further research service nephrology and kidney transplantation at the Clinical Hospital of Barcelona

Referència de l'article

Josep M. Cruzado*, Pablo Moreno†, José V. Torregrosa‡, Omar Taco*, Richard Mast§, Carmen Gómez-Vaquero?, Carolina Polo*, Ignacio Revuelta‡, José Francos†, Joan Torras*, Arantxa García-Barrasa†, Oriol Bestard* and Josep M. Grinyó*. A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism. JASN December 8, 2015. doi:10.1681/ASN.2015060622

IDIBELL-Bellvitge Biomedical Research Institute

Related Kidney Transplant Articles from Brightsurf:

The effects of social determinants of health on kidney transplant candidates
Social determinants of health are associated with patient-reported outcomes in adults who are eligible to undergo kidney transplantation evaluations.

Tailored education system to benefit kidney transplant patients
Researchers find their computer-tailored education system, 'Your Path to Transplant' increases knowledge and readiness to pursue kidney transplant.

Kidney transplant, the cost of accounting for patients' preferences
Taking into account patients' preferences can help speed up the organ allocation process and improve the life quality of the recipients, as shown by a joint study conducted by Ca' Foscari University and the University of Padua

New hope for kidney revival for transplant
Cell therapy delivered directly to the kidney can revive a 'marginal' organ, improving function and could offer new hope for providing more kidneys for transplant.

Are kidney transplant patients at higher risk? The European experience
The risk of death is relatively high in kidney transplant patients admitted to hospital with COVID-19.

The economic burden of kidney transplant failure in the United States
A recent analysis published in the American Journal of Transplantation estimates that for the average US patient who has undergone kidney transplantation, failure of the transplanted organ (graft failure) will impose additional medical costs of $78,079 and a loss of 1.66 quality-adjusted life years.

Mixed chimerism improves long-term kidney transplant outlook
Mixed chimerism - the continued mixing of donor and recipient blood cells following a transplant of blood progenitor cells - could improve outcomes for kidney transplant recipients, according to a new clinical study in about 50 patients.

Kidney paired donation is an excellent option for transplant candidates
An analysis compared transplant recipients who received kidneys through national kidney paired donation and those who received kidneys from other living donors (such as relatives, friends or other paired exchange mechanisms).

Mediterranean diet may help preserve the kidney health of transplant recipients
In a study of kidney transplant recipients, those with higher adherence to the Mediterranean diet were less likely to experience kidney function loss.

New blood test can detect rejection by antibodies after kidney transplant
A group of European scientists led by KU Leuven has found a biomarker that can identify patients with symptoms of kidney rejection symptoms after a transplant as a result of antibodies.

Read More: Kidney Transplant News and Kidney Transplant Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.